Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBR 830 absolute bioavailability and pharmacokinetics study in healthy volunteers
NL-OMON42954Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of telazorlimab in autoimmune disease (2 arms), sponsored by Glenmark Pharmaceuticals SA. Primary endpoint: Absolute bioavailability of GBR 830 after subcutaneous administration. Started Jan 2017; status: active, not recruiting.
02
Drugs
telazorlimab
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON42954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42954.